ejlperello

3 ms·

1. 1.▲
   by ejlperello 11y ago

   The CRISPR IP battle is being fought between universities, not corporations. CRISPR aside, the IP situation in biotech and specifically in synthetic biology (parts-based biology) is not a good one. Currently there exists IP around many smal
2. 2.▲
   by ejlperello 11y ago

   My take is that we will see it used on cell therapies like CAR-T. Id point out that Novartis and Intellia have signed a deal to this effect - see link below. Immunotherapy is likely a clear win for this kind of genome editing technology. An
3. 3.▲
   by ejlperello 11y ago

   Hi there, this is Edward (I spoke at the HN London event a few weeks ago on CRISPR - https://vimeo.com/137001197 ). I'd encourage you to get in touch with us at Desktop Genetics. We are always on the lookout for talente